12,372 trials
Thrombotic Thrombocytopenic Purpura
Primary: Percentage of Participants Who Achieved Remission Without Requirement of Therapeutic Plasma Exchange During Overall Study Period — 93.5 percentage of participants
Respiratory Syncytial Virus
Primary: Part A: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) Within 7 Days After Day 1 Injection — 147; 395; 291 Participants
Triple-Negative Breast Cancer
Primary: Percentage of Participants With Treatment-emergent Grade ≥3 Adverse Events (AEs) — 46.70 percentage of participants
Vasomotor Symptoms · Menopausal Symptoms
Primary: Mean Change in Weekly Frequency of Moderate to Severe Vasomotor Symptoms (VMS) From Baseline to Week 4 and Week 12 -- (Efficacy Study Part) — -39.77; -40.11; -31.82…
Respiratory Syncytial Virus Infections
Primary: Adjusted Geometric Mean Titers (GMT) of Respiratory Syncytial Virus-A (RSV-A) Neutralizing Titers at 1 Month After the RSVPreF3 OA Vaccination — 7885.8; 8803.4 Titers
Atopic Dermatitis Eczema
Primary: Number of Participants With ≥1 Treatment-emergent Adverse Event (TEAE) — 151; 90; 189; 91 Participants
Atopic Dermatitis Eczema
Primary: Achievement of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Success at Week 4 — 25.4; 10.7 percentage of participants — p=<0.0001
Inherited Mitochondrial Disease
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 91 Participants
Diffuse Large B-Cell Lymphoma
Primary: Stage 1: Number of Participants With Adverse Events (AEs) — 14 Participants
Allergic Fungal Rhinosinusitis
Primary: Change From Baseline to Week 52 in Opacification of Sinuses Assessed by CT Scan Using the LMK Score — -1.81; -9.17 score on a scale — p=<0.0001
Migraine
Primary: Mean Change From Baseline in Monthly Average Number of Migraine Days During 12-Week Period After the First Dose of Study Drug — -3.7; -3.8 days/month — p=0.8484
Chronic Heart Failure With Reduced Ejection Fraction
Primary: Time to First Occurrence of Composite Endpoint of Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization: Participants With an Event Per 100 Patient-Years…
Mania (Neurotic)
Primary: Rate of Relapse — .11; .13 Proportion of Participants
Macular Edema Secondary to Retinal Vein Occlusion
Primary: Change From Baseline in BCVA Measured by the ETDRS Letter Score at Week 36 — 17.5; 17.4; 18.3 Letters — p=<0.0001
HIV Prevention
Primary: PrEP Uptake — 16.2; 11.4 days